- Home
- TNYA
as of 03-24-2026 3:41pm EST
$0.74
$0.01
-1.56%
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 178.5M | IPO Year: | 2021 |
| Target Price: | $5.33 | AVG Volume (30 days): | 5.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.59 | EPS Growth: | 54.96 |
| 52 Week Low/High: | $0.36 - $2.35 | Next Earning Date: | 03-11-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1456.12% |
| P/E Ratio: | -1.27 | Index: | N/A |
| Free Cash Flow: | -68882000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Tenaya Therapeutics Inc. (TNYA)
COLUMN GROUP III GP, LP
Sell
10% Owner
TNYA Feb 25, 2026
Avg Cost/Share
$0.56
Shares
3,511,826
Total Value
$1,975,050.94
Owned After
0
COLUMN GROUP III GP, LP
Sell
10% Owner
TNYA Feb 24, 2026
Avg Cost/Share
$0.62
Shares
658,440
Total Value
$405,138.13
Owned After
0
COLUMN GROUP III GP, LP
Sell
10% Owner
TNYA Feb 23, 2026
Avg Cost/Share
$0.60
Shares
306,000
Total Value
$182,743.20
Owned After
0
COLUMN GROUP III GP, LP
Sell
10% Owner
TNYA Feb 20, 2026
Avg Cost/Share
$0.61
Shares
523,734
Total Value
$322,044.04
Owned After
0
Tingley Whittemore
Sell
Chief Medical Officer
TNYA Feb 17, 2026
Avg Cost/Share
$0.64
Shares
5,160
Total Value
$3,318.72
Owned After
218,618
Higa Tomohiro
Sell
SVP, Finance
TNYA Feb 17, 2026
Avg Cost/Share
$0.64
Shares
3,469
Total Value
$2,231.35
Owned After
119,752
COLUMN GROUP III GP, LP
Sell
10% Owner
TNYA Feb 11, 2026
Avg Cost/Share
$0.68
Shares
4,056,573
Total Value
$2,761,714.90
Owned After
0
COLUMN GROUP III GP, LP
Sell
10% Owner
TNYA Feb 10, 2026
Avg Cost/Share
$0.82
Shares
343,717
Total Value
$280,507.44
Owned After
0
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| COLUMN GROUP III GP, LP | TNYA | 10% Owner | Feb 25, 2026 | Sell | $0.56 | 3,511,826 | $1,975,050.94 | 0 | |
| COLUMN GROUP III GP, LP | TNYA | 10% Owner | Feb 24, 2026 | Sell | $0.62 | 658,440 | $405,138.13 | 0 | |
| COLUMN GROUP III GP, LP | TNYA | 10% Owner | Feb 23, 2026 | Sell | $0.60 | 306,000 | $182,743.20 | 0 | |
| COLUMN GROUP III GP, LP | TNYA | 10% Owner | Feb 20, 2026 | Sell | $0.61 | 523,734 | $322,044.04 | 0 | |
| Tingley Whittemore | TNYA | Chief Medical Officer | Feb 17, 2026 | Sell | $0.64 | 5,160 | $3,318.72 | 218,618 | |
| Ali Faraz | TNYA | Chief Executive Officer | Feb 17, 2026 | Sell | $0.64 | 14,862 | $9,556.66 | 452,415 | |
| Higa Tomohiro | TNYA | SVP, Finance | Feb 17, 2026 | Sell | $0.64 | 3,469 | $2,231.35 | 119,752 | |
| COLUMN GROUP III GP, LP | TNYA | 10% Owner | Feb 11, 2026 | Sell | $0.68 | 4,056,573 | $2,761,714.90 | 0 | |
| COLUMN GROUP III GP, LP | TNYA | 10% Owner | Feb 10, 2026 | Sell | $0.82 | 343,717 | $280,507.44 | 0 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Mar 11, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYMar 11, 2026 · 100% conf.
AI Prediction BUY
1D
+6.57%
$0.92
Act: +2.31%
5D
+18.34%
$1.02
20D
+12.78%
$0.97
Price: $0.86 Prob +5D: 100% AUC: 1.000
0001193125-26-102170
8-K
0001858848false00018588482026-03-112026-03-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 11, 2026
Tenaya Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40656
81-3789973
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
171 Oyster Point Boulevard Suite 500
South San Francisco, California
94080
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (650) 825-6990
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
TNYA
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On March 11, 2026, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2025 (“Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.
Description
99.1
Press Release of Tenaya Therapeutics, Inc., dated March 11, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TENAYA THERAPEUTICS, INC.
By:
/s/ Jennifer Drimmer Rokovich
Jennifer Drimmer Rokovich
General Counsel and Secretary
Date: March 11, 2026
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 10, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 10, 2025 · 100% conf.
AI Prediction SELL
1D
+0.46%
$1.45
Act: -1.39%
5D
-10.33%
$1.29
Act: -12.50%
20D
-1.16%
$1.42
Act: -2.08%
Price: $1.44 Prob +5D: 0% AUC: 1.000
0001193125-25-273230
8-K
0001858848false00018588482025-11-102025-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 10, 2025
Tenaya Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40656
81-3789973
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
171 Oyster Point Boulevard Suite 500
South San Francisco, California
94080
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (650) 825-6990
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
TNYA
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 10, 2025, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025 (“Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.
Description
99.1
Press Release of Tenaya Therapeutics, Inc., dated November 10, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TENAYA THERAPEUTICS, INC.
By:
/s/ Jennifer Drimmer Rokovich
Jennifer Drimmer Rokovich
General Counsel and Secretary
Date: November 10, 2025
2025 Q2 Q2 2025 Earnings
8-K Aug 6, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 6, 2025
0000950170-25-104164
8-K
false000185884800018588482025-08-062025-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 06, 2025
Tenaya Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-40656
81-3789973
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
171 Oyster Point Boulevard Suite 500
South San Francisco, California
94080
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (650) 825-6990
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
TNYA
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 6, 2025, Tenaya Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025 (“Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.
Description
99.1
Press Release of Tenaya Therapeutics, Inc., dated August 6, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TENAYA THERAPEUTICS, INC.
By:
/s/ Jennifer Drimmer Rokovich
Jennifer Drimmer Rokovich
General Counsel and Secretary
Date: August 6, 2025
Latest Tenaya Therapeutics Inc. News
TNYA Breaking Stock News: Dive into TNYA Ticker-Specific Updates for Smart Investing
Compare TNYA vs Leading Stocks
See how TNYA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TNYA Tenaya Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.